What is IONS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.72B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IONS?

P/E (TTM) is n/a and 52-week range is $42.08 to $86.74 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IONS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IONS?

The company profile lists revenue (TTM) near $878M, net income (TTM) near -$56.78B, EPS (TTM) near -$3.47 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ionis Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carlsbad, California, US, 166.2M shares outstanding, ISIN US4622221004 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Ionis Pharmaceuticals, Inc.

$IONS

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Employees

1,402

Website

www.ionis.com/

IPO

1991-05-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US4622221004

Headquarters

Carlsbad, California, US

Shares outstanding

166.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

110.21%

Browse other companiesFree AI scores and summaries for more stocks